
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id><journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id><journal-title-group><journal-title>Frontiers in Oncology</journal-title></journal-title-group><issn pub-type="epub">2234-943X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">33194575</article-id><article-id pub-id-type="pmc">7642822</article-id><article-id pub-id-type="doi">10.3389/fonc.2020.01776</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oncology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Mitochondrial Fission Factor (MFF) Inhibits Mitochondrial Metabolism and Reduces Breast Cancer Stem Cell (CSC) Activity</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>S&#x000e1;nchez-Alvarez</surname><given-names>Rosa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/985491/overview"/></contrib><contrib contrib-type="author"><name><surname>De Francesco</surname><given-names>Ernestina Marianna</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/558986/overview"/></contrib><contrib contrib-type="author"><name><surname>Fiorillo</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/665143/overview"/></contrib><contrib contrib-type="author"><name><surname>Sotgia</surname><given-names>Federica</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/269370/overview"/></contrib><contrib contrib-type="author"><name><surname>Lisanti</surname><given-names>Michael P.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="c002"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/269289/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Division of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester</institution>, <addr-line>Manchester</addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><sup>2</sup><institution>Translational Medicine, School of Science, Engineering and Environment (SEE), Biomedical Research Centre (BRC), University of Salford</institution>, <addr-line>Greater Manchester</addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Clinical and Experimental Medicine, University of Catania, and ARNAS Garibaldi</institution>, <addr-line>Catania</addr-line>, <country>Italy</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Philipp E. Scherer, University of Texas Southwestern Medical Center, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Hsueh-Wei Chang, Kaohsiung Medical University, Taiwan; Daeseok Kim, University of Texas Southwestern Medical Center, United States</p></fn><corresp id="c001">*Correspondence: Federica Sotgia <email>fsotgia@gmail.com</email></corresp><corresp id="c002">Michael P. Lisanti <email>michaelp.lisanti@gmail.com</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Cancer Metabolism, a section of the journal Frontiers in Oncology</p></fn><fn fn-type="other" id="fn002"><p>&#x02020;These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>10</volume><elocation-id>1776</elocation-id><history><date date-type="received"><day>23</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>10</day><month>8</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 S&#x000e1;nchez-Alvarez, De Francesco, Fiorillo, Sotgia and Lisanti.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>S&#x000e1;nchez-Alvarez, De Francesco, Fiorillo, Sotgia and Lisanti</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Elevated mitochondrial biogenesis and metabolism represent key features of breast cancer stem cells (CSCs), whose propagation is conducive to disease onset and progression. Therefore, interfering with mitochondria biology and function may be regarded as a useful approach to eradicate CSCs. Here, we used the breast cancer cell line MCF7 as a model system to interrogate how mitochondrial fission contributes to the development of mitochondrial dysfunction toward the inhibition of metabolic flux and stemness. We generated an isogenic MCF7 cell line transduced with Mitochondrial Fission Factor (MCF7-MFF), which is primarily involved in mitochondrial fission. We evaluated the biochemical, molecular and functional properties of MCF7-MFF cells, as compared to control MCF7 cells transduced with the empty vector (MCF7-Control). We observed that MFF over-expression reduces both mitochondrial mass and activity, as evaluated using the mitochondrial probes MitroTracker Red and MitoTracker Orange, respectively. The analysis of metabolic flux using the Seahorse XFe96 revealed the inhibition of OXPHOS and glycolysis in MCF7-MFF cells, suggesting that increased mitochondrial fission may impair the biochemical properties of these organelles. Notably, CSCs activity, assessed by 3D-tumorsphere assays, was reduced in MCF7-MFF cells. A similar trend was observed for the activity of ALDH, a well-established marker of stemness. We conclude that enhanced mitochondrial fission may compromise CSCs propagation, through the impairment of mitochondrial function, possibly leading to a quiescent cell phenotype. Unbiased proteomic analysis revealed that proteins involved in mitochondrial dysfunction, oxidative stress-response, fatty acid metabolism and hypoxia signaling are among the most highly up-regulated in MCF7-MFF cells. Of note, integrated analysis of top regulatory networks obtained from unbiased proteomics in MCF7-MFF cells predicts that this cell phenotype activates signaling systems and effectors involved in the inhibition of cell survival and adhesion, together with the activation of specific breast cancer cell death programs. Overall, our study shows that unbalanced and abnormal activation of mitochondrial fission may drive the impairment of mitochondrial metabolic function, leading to inhibition of CSC propagation, and the activation of quiescence programs. Exploiting the potential of mitochondria to control pivotal events in tumor biology may, therefore, represent a useful tool to prevent disease progression.</p></abstract><kwd-group><kwd>mitochondrial fission factor</kwd><kwd>CSCs</kwd><kwd>mitochondrial metabolism</kwd><kwd>breast cancer</kwd><kwd>mitochondrial dynamics</kwd><kwd>oxidative metabolism</kwd><kwd>metabo-stemness</kwd><kwd>mitochondrial mass</kwd></kwd-group><counts><fig-count count="8"/><table-count count="7"/><equation-count count="0"/><ref-count count="49"/><page-count count="17"/><word-count count="9618"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Mitochondrial function is essential for supplying energy to fuel cancer cell growth and metastatic dissemination (<xref rid="B1" ref-type="bibr">1</xref>). Furthermore, enhanced mitochondrial metabolism has emerged as one of the novel features of cancer stem cells (CSCs), which exhibit tumorigenic and self-renewal properties, carry metastatic potential and provide resistance to anti-cancer therapies (<xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref>). In this regard, cancer cells biologically recapitulate certain stemness features, including anchorage-independent growth and higher tumor-initiating capacity, as well as increased mitochondrial mass, biogenesis and protein translation, across multiple tumor types (<xref rid="B5" ref-type="bibr">5</xref>). These observations, which clearly suggest a key role for mitochondria in CSC maintenance and propagation, are corroborated by the evidence that mitochondrial metabolic function and OXPHOS are augmented in cancer cells with stemness features, as compared to the non-stem cancer cell sub-population (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). As a consequence of these findings, the ability of several classes of mitochondria-interfering agents to inhibit CSC dissemination has been explored, as reviewed in De Francesco et al. (<xref rid="B8" ref-type="bibr">8</xref>). In this regard, several antibiotics that impair mitochondrial protein translation, as a side effect, have been shown to be effective in depleting the CSC population <italic>in vitro</italic>, as well as in clinical studies (<xref rid="B9" ref-type="bibr">9</xref>&#x02013;<xref rid="B13" ref-type="bibr">13</xref>). As such, a deeper understanding of mitochondrial biology in cancer would pave the way toward the identification of targeted therapeutics, aimed at selectively halting and eradicating CSCs.</p><p>Adequate mitochondrial function also depends on the intrinsic mechanical changes in the dynamic structure and architecture of these organelles (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). For instance, changes in mitochondrial size and shape, as well as localization, are critical for the homeostasis of the energetic machinery. The main macro-mechanical events regulating mitochondrial architecture are represented by cycles of mitochondrial fusion and fission (fragmentation), that together constitute a mitochondrial network (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). Given their important role in maintaining mitochondria homeostasis, fusion and fission are tightly regulated processes, whose de-regulation is associated with metabolic dysfunction, that may precede the establishment of pathological phenotypes (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B17" ref-type="bibr">17</xref>). In cancer, the elevated nutrient demands of proliferating cells are mainly fulfilled by drastic changes in energetic metabolism, largely supported by mitochondria, whose changes in function and shape are pivotal to tumor growth (<xref rid="B1" ref-type="bibr">1</xref>). Indeed, several oncogenic signals have been shown to influence the number of mitochondria, which is dependent on fusion-fission dynamics (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B18" ref-type="bibr">18</xref>). Likewise, aberrant mitochondrial fission results in massive mitochondrial fragmentation, resulting in inhibition of oxidative metabolism and depletion of ATP (<xref rid="B19" ref-type="bibr">19</xref>). Mitochondrial Fission Factor (MFF) is an integral membrane protein of the outer mitochondrial membrane that serves as the main molecular mediator regulating mitochondria fragmentation (<xref rid="B20" ref-type="bibr">20</xref>). During fission, the cytosolic protein Drp1 is recruited to the mitochondrial surface via MFF and the proteins Fis1 (mitochondrial fission protein 1), MiD49 and MiD51 (mitochondrial dynamics proteins of 49 and 51 kDa, respectively) (<xref rid="B21" ref-type="bibr">21</xref>&#x02013;<xref rid="B23" ref-type="bibr">23</xref>). Oligomeric Drp1 complexes are, thereafter, assembled into specific structures named <italic>puncta</italic>, which wrap around mitochondrial tubules, forcing them toward the fission reaction (<xref rid="B24" ref-type="bibr">24</xref>). Several studies have demonstrated that increased MFF expression is required for successive mitochondrial fission and is associated with disease states (<xref rid="B25" ref-type="bibr">25</xref>). Nevertheless, the role of MFF in regulating mitochondrial dynamics in breast cancer has not been thoroughly elucidated.</p><p>Herein, we provide evidence that aberrant MFF expression in breast cancer cells drastically inhibits mitochondrial mass and function, associated with a reduction of mitochondrial oxidative metabolism and ATP depletion. Proteomic profiling of MFF-overexpressing breast cancer cells reveals a phenotype associated with the inhibition of mitochondrial metabolism and a quiescent cell state. Biologically, MFF-overexpressing breast cancer cells exhibit impaired 3D mammosphere formation capacity, suggesting that the manipulation of mitochondrial structure and dynamics may represent a useful tool to control stemness traits in breast cancer.</p></sec><sec sec-type="materials and methods" id="s2"><title>Materials and Methods</title><sec><title>Cell Culture</title><p>MCF7 human breast cancer cells were purchased from ATCC. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mL of penicillin, 100 &#x003bc;g/mL of streptomycin and 2 mM Glutamax (ThermoScientific), in a 37&#x000b0;C humidified atmosphere containing 5% CO<sub>2</sub>, unless otherwise noted.</p></sec><sec><title>Lentiviral Gene Transduction</title><p>Lentiviral plasmids, packaging cells and reagents were from Genecopoeia. Forty-eight hours after seeding, 293Ta packaging cells were transfected with lentiviral vectors encoding the mitochondrial fission factor (MFF, EX-Z4766-Lv-105), or empty vector (EV, EX-NEG-Lv105), using the Lenti-PacTM HIV Expression Packaging Kit, according to the manufacturer's instructions. Two days post-transfection, lentivirus-containing culture medium was passed through a 0.45 &#x003bc;m filter and added to the target cells (MCF7 cells) in the presence of 5 &#x003bc;g/ml polybrene. Transduced MCF7 cells were selected with 2.5 &#x003bc;g/ml puromycin.</p></sec><sec><title>Western Blotting</title><p>Western blotting of stably transduced MCF7 cells was used to evaluate the efficiency of transduction. Briefly, 70&#x02013;80% confluent stably-transduced MCF7 cells (harboring MFF and the respective Ex-Negative control) were harvested in lysis buffer (10 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, and 60 mM n-octyl-glucoside), containing protease (Roche) and phosphatase inhibitors (Sigma) and kept at 4&#x000b0;C for 40 min with rotation. Lysates were cleared by centrifugation for 10 min at 10, 000 &#x000d7; g and supernatants were collected. Equal amounts of protein lysate, as determined by using the BCA protein assay kit (Pierce), were diluted in SDS sample buffer and dry-boiled for 5 min, prior to separation by SDS-PAGE using 4&#x02013;20% acrylamide gels (Biorad). Samples were then blotted onto nitrocellulose membranes (Biorad), blocked in 5% milk in TBS-Tween 20 (P9416, Sigma) for 1 h and probed with antibodies directed against MFF (Abcam), or &#x003b2;-actin (Sigma), which was used as loading control. Bound antibodies were detected using a horseradish peroxidase-conjugated secondary antibody (ab6789 and ab6721, Abcam) and the signal was visualized using Supersignal West Pico chemiluminescent substrate (ThermoScientific).</p></sec><sec><title>Mitochondrial Staining</title><p>Mitochondrial activity was assessed using the fluorescent probe MitoTracker Orange (CM-H2TMRos-reduced form) (ThermoFisher), whose accumulation in mitochondria is dependent upon membrane potential. Mitochondrial mass was determined using the fluorescent probe MitoTracker Deep-Red (ThermoFisher), which localizes to mitochondria regardless of mitochondrial membrane potential. Stably transduced MCF7 cells (harboring MFF or the Ex-Negative Control) were seeded for 48 h. After 48 h, the cells were incubated with pre-warmed MitoTracker staining solution (diluted in DMEM without serum to a final concentration of 10 nM) for 30 min at 37&#x000b0;C. All subsequent steps were performed in the dark. Cells were washed in PBS, harvested, and re-suspended in 300 &#x003bc;L of PBS/Ca<sup>2+</sup>Mg<sup>2+</sup>. Cells were then analyzed by flow cytometry using Fortessa (BD Bioscience). Data analysis was performed using FlowJo software. Results are the average of the mean of three independent experiments, were normalized to the control (Ex-Neg) and are expressed as percentages of mean fluorescence intensity. At least 4 biological replicates were performed in each experiment.</p></sec><sec><title>Seahorse XFe96 Metabolic Flux Analysis</title><p>Real time oxygen consumption rates (OCRs) and Extracellular acidification rates (ECARs) were determined for stably transduced MCF7 cells using the Seahorse Extracellular Flux (XFe96) analyzer (Seahorse Bioscience, MA, USA). Briefly, 10,000 cells per well were seeded into XFe96 well cell culture plates and incubated overnight with complete medium to allow attachment. After 24 h of incubation, cells were washed in either pre-warmed XF assay media containing 2 mM glutamine, pH 7.4 for ECAR measurements or in XF assay media supplemented with 10 mM glucose, 1 mM Pyruvate, 2 mM L-glutamine and adjusted at 7.4 pH for OCR measurements. Cells were then maintained in 175 &#x003bc;L/well of XF assay media at 37&#x000b0;C, in a non-CO<sub>2</sub> incubator for 1 h. During the incubation time, 25 &#x003bc;L of 80 mM glucose, 9 &#x003bc;M oligomycin, and 1M 2-deoxyglucose were loaded for ECAR measurement or 10 &#x003bc;M oligomycin, 9 &#x003bc;M FCCP, 10 &#x003bc;M rotenone, 10 &#x003bc;M antimycin A were loaded for OCR measurements, in XF assay media into the injection ports in the XFe96 sensor cartridge. Measurements were normalized by protein content, determined by SRB. Data sets were analyzed by employing XFe96 software and GraphPad Prism software, using Student's <italic>t</italic>-test calculations. Results are the average of the mean of three independent experiments normalized to the control and are expressed as percentages of mpH/min/SRB for ECAR or pmol/min/SRB for OCR measurements. At least six biological replicates were performed in each experiment.</p></sec><sec><title>3D Mammosphere Culture</title><p>A single cell suspension of stably transduced MCF7 cells was prepared using enzymatic (1x Trypsin-EDTA, Sigma Aldrich), and manual disaggregation (25 gauge needle) as previously described (<xref rid="B26" ref-type="bibr">26</xref>). Cells were plated at a density of 500 cells/cm<sup>2</sup> in DMEM-F12 phenol free supplemented with B27, 20,ng/ml EGF and 1% Pen/Strep in non-adherent conditions, in culture dishes coated with 2-hydroxyethylmethacrylate (poly-HEMA, Sigma-Aldrich). Cells were grown for 5 days and maintained in a humidified incubator at 37&#x000b0;C. After 5 days in culture, spheres &#x0003e; 50 &#x003bc;m were counted using an eyepiece graticule. Results are the average of the mean of three independent experiments normalized to the control (Ex-Neg) and are expressed as percentage of cells plated which formed spheres. Three biological replicates were performed in each experiment.</p></sec><sec><title>Aldefluor Assay</title><p>ALDH activity was assessed in stably transduced MCF7 cells, which were seeded in monolayer for 48 h. The ALDEFLUOR kit (StemCell Technologies) was used to isolate the population with high ALDH enzymatic activity by flow cytometry (Fortessa, BD Bioscience). Briefly, cells were harvested and incubated in 1 ml of ALDEFLUOR assay buffer containing ALDH substrate (5 &#x003bc;l/ml) for 40 min at 37&#x000b0;C. In each experiment, a sample of cells was stained under identical conditions with 30 mM of diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor, as a negative control. The ALDH-positive population was established, according to the manufacturer's instructions and was evaluated using 30,000 cells.</p></sec><sec><title>Proteomics and Ingenuity Pathway Analysis (IPA)</title><p>Samples were submitted to the CRUK Proteomics Core Facility, for label-free proteomic analysis. Proteomics and statistical analyses were carried out on a fee-for-service basis by Smith and his colleagues, at the Proteomics Core Facility at the Cancer Research UK Manchester Institute, University of Manchester. Briefly, stably transduced MCF7 cells were cultured in complete media at a density of 1.8 &#x000d7; 10<sup>6</sup> in 10 cm dish. The day after plating, the media was changed to DMEM with 10% NuSerum, Pen-Strep and Glutamax. After 24 h, 70&#x02013;75% of confluence was reached. Then, cells were washed twice with PBS and RIPA lysis buffer was added without protease inhibitors to detach the cells. The lysates were collected into pre-cooled tubes and kept on ice for 10 min. After centrifugation, the supernatants were collected and the samples were flash-frozen using liquid nitrogen. Previously, a small aliquot was removed for protein quantification. Samples were kept at &#x02212;80&#x000b0;C until further analysis. Samples were subjected to proteomics following a protocol previously described (<xref rid="B27" ref-type="bibr">27</xref>). Briefly, cell lysates were prepared for trypsin digestion by sequential reduction of disulfide bonds with TCEP and alkylation with MMTS. Then, the peptides were extracted and prepared for LC-MS/MS. All LC-MS/MS analyses were performed on an LTQ Orbitrap XL mass spectrometer (ThermoScientific) coupled to an Ultimate 3000 RSLCnano system (ThermoScientific). Xcalibur raw data files acquired on the LTQ-Orbitrap XL were directly imported into Progenesis LCMS software (Waters Corp.) for peak detection and alignment. Data were analyzed using the Mascot search engine. Five replicates were analyzed for each sample type (N = 5). Statistical analyses were performed using ANOVA and a 1.5-fold-change in protein levels, with a <italic>p</italic> &#x0003c; 0.05 were considered significant. The molecular function and biological pathways of the differentially expressed proteins were performed by the unbiased interrogation and analysis of proteomic data sets using IPA (Ingenuity systems, <ext-link ext-link-type="uri" xlink:href="http://www.ingenuity.com">http://www.ingenuity.com</ext-link>). IPA assists with data interpretation, via the grouping of differentially expressed genes or proteins into known functions and pathways. Pathways with a z score of &#x0003e; +2 were considered as significantly activated, while pathways with a z score of &#x0003c;-2 were considered as significantly inhibited.</p></sec><sec><title>Statistical Analysis</title><p>Data is represented as the mean &#x000b1; standard error of the mean (SEM), taken over &#x02265;3 independent experiments, with &#x02265;3 technical replicates per experiment, unless stated otherwise. Statistical significance was measured, using the Student <italic>t</italic>-test. A <italic>p</italic> &#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>Cancer stem cells (CSCs) are characterized by elevated mitochondrial biogenesis and metabolism (<xref rid="B2" ref-type="bibr">2</xref>). However, mitochondrial function is also largely dependent on a well-regulated balance between mitochondrial fusion and fission dynamics (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B23" ref-type="bibr">23</xref>). In fact, aberrantly activated fission results in mitochondrial fragmentation, which is associated to mitochondrial dysfunction.</p><p>Here, we interrogated how unopposed mitochondrial fission may promote alterations in mitochondrial biology and function, leading to inhibition of CSCs propagation in breast cancer.</p><sec><title>MFF Inhibits Mitochondrial Biogenesis</title><p>In order to investigate the role of MFF in the regulation of mitochondrial activity in breast cancer cells, we generated an isogenic MCF7 cell line harboring MFF (MCF7-MFF), together with a matched isogenic cell line harboring the empty vector, which served as a control (MCF7-Control). After verifying MFF-overexpression by Western blotting (<xref ref-type="fig" rid="F1">Figure 1A</xref>), the newly generated cell lines were subjected to functional phenotypic characterization. As a first step, cells were analyzed by FACS analysis using MitoTracker Deep-Red-FM, as a probe to estimate mitochondrial mass. As shown in <xref ref-type="fig" rid="F1">Figure 1C</xref>, mitochondrial content was reduced by 30% in MCF7-MFF cells. A similar trend was observed for the evaluation of mitochondrial activity by FACS analysis, using the probe Mito-Orange (<xref ref-type="fig" rid="F1">Figure 1B</xref>), suggesting an overall impairment in mitochondrial content and function in the presence of MFF-overexpression.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Mitochondrial fission factor (MFF) decreases mitochondrial activity and mass. <bold>(A)</bold> Evaluation of MFF overexpression. MCF7 cells, stably transduced with a lentiviral vector encoding for mitochondrial fission factor (MCF-MFF) or the empty-vector (MCF-7 Control), were subjected to protein extraction and immunoblotted for MFF. &#x003b2;-actin is shown as equal loading control. <bold>(B,C)</bold> MFF overexpression decreases mitochondrial activity and mass. Stably transduced MCF7 cells harboring MFF (MCF-MFF) and the respective empty-vector (MCF-7 Control) were seeded for 24 h and then mitochondrial activity and mitochondrial mass were quantitated by FACS analysis using the probes MitoTracker Orange <bold>(B)</bold> and MitoTracker Deep-Red <bold>(C)</bold>. At least four replicates were performed in each experiment. Results are the average of the mean of three independent experiments and are expressed as percentages normalized to the control &#x000b1; SEM. ***<italic>p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="fonc-10-01776-g0001"/></fig></sec><sec><title>MFF Inhibits Breast Cancer Cell Metabolism</title><p>Data shown above immediately suggest that MFF may interfere with mitochondrial oxidative metabolism. To test this hypothesis, we directly evaluated metabolic flux using the Seahorse XFe96 and we found that Oxygen Consumption Rates (OCR) were significantly reduced in MCF7-MFF cells (<xref ref-type="fig" rid="F2">Figure 2</xref>). More specifically, basal respiration and maximal respiration were reduced by nearly 40% (<xref ref-type="fig" rid="F2">Figures 2B,E</xref>); accordingly, ATP levels were also depleted (<xref ref-type="fig" rid="F2">Figure 2D</xref>). Notably, the analysis of Extracellular Acidification Rates (ECR) demonstrated that also the glycolytic pathway is inhibited in MCF7-MFF cells (<xref ref-type="fig" rid="F3">Figure 3</xref>). In particular, a nearly 40 % decrease in glycolysis and glycolytic capacity (<xref ref-type="fig" rid="F3">Figures 3B,C</xref>) were observed; an inhibitory, though not significant, trend was also observed for glycolytic reserve and non-glycolytic acidification (<xref ref-type="fig" rid="F3">Figures 3D,E</xref>). Taken together, these data indicate that MFF over-expression negatively affects the metabolic cell machinery, by interfering with both oxidative phosphorylation and glycolysis in breast cancer cells.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Mitochondrial fission factor (MFF) reduces mitochondrial respiration. The metabolic profile of stably transduced MCF7 cells harboring MFF (MCF-MFF) and the respective empty-vector (MCF-7 Control) was examined using the Seahorse XFe96 analyzer. <bold>(A)</bold> Oxygen consumption rate (OCR) is significantly reduced in cells transduced with MFF as compared to control cells. <bold>(B&#x02013;F)</bold> Significant reductions in respiration (basal and maximal), proton leak, ATP levels and non-mitochondrial derived OCR were observed in MCF7 cells transduced with MFF as compared to the control cells. At least six replicates were performed in each experiment. Results are the average of the mean of three independent experiments and are expressed as percentages normalized to the control &#x000b1; SEM. *<italic>p</italic> &#x0003c; 0.05, **<italic>p</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="fonc-10-01776-g0002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Mitochondrial fission factor (MFF) reduces glycolysis. The metabolic profile of stably transduced MCF7 cells harboring MFF (MCF-MFF) and the respective empty-vector (MCF-7 Control) was examined using the Seahorse XFe96 analyzer. <bold>(A)</bold> Extracellular acidification rate (ECAR) is significantly reduced in cells transduced with MFF as compared to control cells. <bold>(B,C)</bold> Significant reduction in glycolysis and glycolytic capacity were observed in MCF7 cells transduced with MFF as compared to control cells, without significant changes in glycolytic reserve <bold>(D)</bold>, non-glycolytic acidification <bold>(E)</bold>, and glycolytic reserve capacity <bold>(F)</bold>. At least six replicates were performed in each experiment. Results are the average of the mean of three independent experiments and are expressed as percentages normalized to the control &#x000b1; SEM. *<italic>p</italic> &#x0003c; 0.05, ***<italic>p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="fonc-10-01776-g0003"/></fig></sec><sec><title>MFF Inhibits Breast CSC Activity</title><p>We previously established that within the heterogeneous tumor mass, cancer cells exhibiting stemness features are also characterized by an elevated level of mitochondrial function (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B28" ref-type="bibr">28</xref>). On the other hand, strategies aimed at targeting mitochondria have proven to be beneficial in halting CSCs, both in pre-clinical and clinical studies (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). Based on these observations, we investigated whether aberrant mitochondrial fission may affect CSC propagation, together with the impairment of mitochondrial function. For this purpose, we used the 3D tumor-sphere formation assay as readout for CSCs activity. <xref ref-type="fig" rid="F4">Figure 4A</xref> shows that mammosphere formation is inhibited by nearly 50% in MCF7-MFF cells. Likewise, ALDH activity, a surrogate marker of stemness, was reduced by &#x0003e;60% in MCF7-MFF cells (<xref ref-type="fig" rid="F4">Figures 4B,C</xref>). These results clearly indicate that MFF over-expression hampers breast CSCs propagation.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Mitochondrial fission factor (MFF) inhibits 3D-spheroid formation and ALDH activity. <bold>(A)</bold> Evaluation of mammosphere formation efficiency (MFE) in stably transduced MCF7 cells harboring the mitochondrial fission factor (MCF7-MFF) and the respective empty-vector (MCF-7 Control), which were seeded on low-attachment plates for 5 days. Under these conditions, MCF7-MFF cells show a reduction by 45% in the mammosphere forming capacity as compared to MCF7-Control cells. <bold>(B)</bold> Evaluation of ALDEFLUOR activity, an independent marker of CSCs in MCF7 cells harboring MFF (MCF7-MFF) and the respective empty vector control (MCF-Control). Each sample was normalized using diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor, as negative control. <bold>(C)</bold> The tracing of representative samples is shown. Results are the average of the mean of three independent experiments performed in triplicate and are expressed as percentages normalized to the control &#x000b1; SEM. **<italic>p</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="fonc-10-01776-g0004"/></fig></sec><sec><title>Proteomic Profiling Reveals the MFF-Dependent Metabolic, Signaling, and Biological Landscape</title><p>Dysfunctional mitochondria activate a retrograde signaling network that shapes the nuclear transcriptomic program toward the regulation of cell morphology and function, for cells to response to disruption of energy metabolism (<xref rid="B31" ref-type="bibr">31</xref>). Adding to this, several lines of evidence indicate that mitochondrial dynamics might be involved in the regulation of stress signaling (<xref rid="B14" ref-type="bibr">14</xref>). Hence, we sought to depict the metabolic and signaling network landscape of MFF over-expressing breast cancer cells by using an &#x0201c;omics&#x0201d; approach. More specifically, unbiased proteomic analysis was performed in MCF7-MFF as well as in the matched MCF7-Control counterpart. Thereafter, the software Ingenuity Pathway was used to: (i) classify and group the proteins differentially regulated in response to MFF overexpression; (ii) predict how the upstream regulators may cause downstream phenotypic or functional changes in response to MFF overexpression.</p></sec><sec><title>Metabolomic Signature</title><p>Results, shown in <xref rid="T1" ref-type="table">Tables 1</xref>&#x02013;<xref rid="T5" ref-type="table">5</xref>, indicate that increased expression of MFF fosters a transition toward a metabolically quiescent cell phenotype. In particular, proteins involved in mitochondrial biogenesis (<xref rid="T1" ref-type="table">Table 1</xref>), Oxidative Phosphorylation (<xref rid="T2" ref-type="table">Table 2</xref>) and TCA cycle (<xref rid="T3" ref-type="table">Table 3</xref>) are the most strongly down-regulated in MCF7-MFF, as compared to MCF-Control cells. Furthermore, inhibition of proteins involved in the glycolytic and the pentose phosphate pathways is observed in MCF7-MFF cells (<xref rid="T4" ref-type="table">Tables 4</xref>, <xref rid="T5" ref-type="table">5</xref>). Likewise, a higher accumulation of proteins involved in the metabolism of metabolic precursors mainly for Oxidative phosphorylation, TCA cycle and Glycolysis is detected in MCF7-MFF cells, suggesting that the metabolic machinery is inhibited in the presence of enhanced mitochondrial fragmentation (<xref ref-type="fig" rid="F5">Figure 5</xref>). Also, it appears that MFF over-expression triggers the up-regulation of a &#x0201c;toxicity network&#x0201d; of proteins, mainly related to cell metabolism (<xref ref-type="fig" rid="F6">Figure 6</xref>). The most strongly up-regulated &#x0201c;toxicity&#x0201d; proteins are classified as regulators of mitochondrial dysfunction, together with oxidative stress response and fatty acid metabolism (<xref ref-type="fig" rid="F6">Figure 6</xref>). Also, a &#x0201c;toxicity network&#x0201d; of proteins involved in the regulation of mitochondrial membrane potential and hypoxia signaling are engaged as relevant effectors in MCF7-MFF cells (<xref ref-type="fig" rid="F6">Figure 6</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Significant changes in protein levels associated with mitochondrial biogenesis in MCF7 cells over-expressing mitochondrial fission factor (MFF).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Symbol</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Gene name</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Fold change</bold></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="3" rowspan="1"><bold>Mitochondrial biogenesis</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MFN2</td><td valign="top" align="left" rowspan="1" colspan="1">Mitofusin 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;31.184</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MTERF1</td><td valign="top" align="left" rowspan="1" colspan="1">Mitochondrial transcription termination factor 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;5.38</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MTFR1</td><td valign="top" align="left" rowspan="1" colspan="1">Mitochondrial fission regulator 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;9.616</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TFAM</td><td valign="top" align="left" rowspan="1" colspan="1">Transcription factor A, mitochondrial</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.519</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TIMM50</td><td valign="top" align="left" rowspan="1" colspan="1">Translocase of inner mitochondrial membrane 50</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;83.102</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TIMM10B</td><td valign="top" align="left" rowspan="1" colspan="1">Translocase of inner mitochondrial membrane 10 homolog B (yeast)</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;157.576</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TIMM23B</td><td valign="top" align="left" rowspan="1" colspan="1">Translocase of inner mitochondrial membrane 23 homolog B</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.56</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TIMM8B</td><td valign="top" align="left" rowspan="1" colspan="1">Translocase of inner mitochondrial membrane 8 homolog B</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;5.662</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TIMM13</td><td valign="top" align="left" rowspan="1" colspan="1">Translocase of inner mitochondrial membrane 13</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;2.266</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TOMM34</td><td valign="top" align="left" rowspan="1" colspan="1">Translocase of outer mitochondrial membrane 34</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;5.272</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TSFM</td><td valign="top" align="left" rowspan="1" colspan="1">Ts translation elongation factor, mitochondrial</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.635</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">YY1</td><td valign="top" align="left" rowspan="1" colspan="1">YY1 transcription factor</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>Infinity</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SIRT6</td><td valign="top" align="left" rowspan="1" colspan="1">Sirtuin 6</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;8.746</bold></td></tr></tbody></table><table-wrap-foot><p><italic>Fold change of proteins detected in MCF7-MFF vs. MCF7-Control cells. Red: Up-regulated proteins; Green: down-regulated proteins. Proteomics was performed as described in Materials and Methods. Statistical analyses were performed using ANOVA and 1.5-fold-changes in proteins with a p &#x0003c; 0.05 were considered. Dataset containing proteins with significant altered expression profile were imported into the Ingenuity Pathway Analyses (IPA) software, which groups the differentially expressed proteins into known functions and pathways</italic>.</p></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Significant changes in protein levels associated with oxidative phosphorylation in MCF7 cells over-expressing the mitochondrial fission factor (MFF).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Symbol</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Gene name</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Fold change</bold></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="3" rowspan="1"><bold>Oxidative phosphorylation</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATP5A1</td><td valign="top" align="left" rowspan="1" colspan="1">ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>9.846</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATP5B</td><td valign="top" align="left" rowspan="1" colspan="1">ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1781.432</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATP5C1</td><td valign="top" align="left" rowspan="1" colspan="1">ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;2.919</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATP5F1</td><td valign="top" align="left" rowspan="1" colspan="1">ATP synthase, H+ transporting, mitochondrial Fo complex subunit B1</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.216</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATP5H</td><td valign="top" align="left" rowspan="1" colspan="1">ATP synthase, H+ transporting, mitochondrial Fo complex subunit D</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.623</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATP5I</td><td valign="top" align="left" rowspan="1" colspan="1">ATP synthase, H+ transporting, mitochondrial Fo complex subunit E</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.736</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATP5J</td><td valign="top" align="left" rowspan="1" colspan="1">ATP synthase, H+ transporting, mitochondrial Fo complex subunit F6</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.673</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATP5J2</td><td valign="top" align="left" rowspan="1" colspan="1">ATP synthase, H+ transporting, mitochondrial Fo complex subunit F2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;2.37</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATP5L</td><td valign="top" align="left" rowspan="1" colspan="1">ATP synthase, H+ transporting, mitochondrial Fo complex subunit G</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;15.581</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATP5O</td><td valign="top" align="left" rowspan="1" colspan="1">ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;601.813</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COX4I1</td><td valign="top" align="left" rowspan="1" colspan="1">Cytochrome c oxidase subunit 4I1</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.669</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COX4I2</td><td valign="top" align="left" rowspan="1" colspan="1">Cytochrome c oxidase subunit 4I2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;137.623</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COX5A</td><td valign="top" align="left" rowspan="1" colspan="1">Cytochrome c oxidase subunit 5A</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.913</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COX5B</td><td valign="top" align="left" rowspan="1" colspan="1">Cytochrome c oxidase subunit 5B</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.364</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COX6B1</td><td valign="top" align="left" rowspan="1" colspan="1">Cytochrome c oxidase subunit 6B1</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.87</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COX6C</td><td valign="top" align="left" rowspan="1" colspan="1">Cytochrome c oxidase subunit 6C</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.38</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COX7A2</td><td valign="top" align="left" rowspan="1" colspan="1">Cytochrome c oxidase subunit 7A2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;12.37</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COX7A2L</td><td valign="top" align="left" rowspan="1" colspan="1">Cytochrome c oxidase subunit 7A2 like</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.617</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CYB5A</td><td valign="top" align="left" rowspan="1" colspan="1">Cytochrome b5 type A</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.802</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CYC1</td><td valign="top" align="left" rowspan="1" colspan="1">Cytochrome c1</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>16.811</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CYCS</td><td valign="top" align="left" rowspan="1" colspan="1">Cytochrome c, somatic</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.821</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MT-ATP6</td><td valign="top" align="left" rowspan="1" colspan="1">ATP synthase F0 subunit 6</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;280.464</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MT-CO2</td><td valign="top" align="left" rowspan="1" colspan="1">Cytochrome c oxidase subunit II</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>4.759</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MT-ND1</td><td valign="top" align="left" rowspan="1" colspan="1">NADH dehydrogenase, subunit 1 (complex I)</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>11.786</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MT-ND2</td><td valign="top" align="left" rowspan="1" colspan="1">Mitochondrially encoded NADH dehydrogenase 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;7.366</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MT-ND5</td><td valign="top" align="left" rowspan="1" colspan="1">NADH dehydrogenase, subunit 5 (complex I)</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;8.753</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFA2</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit A2</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.51</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFA4</td><td valign="top" align="left" rowspan="1" colspan="1">NDUFA4, mitochondrial complex associated</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.201</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFA5</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit A5</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.527</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFA6</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit A6</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;112.999</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFA8</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit A8</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>45.057</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFA9</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit A9</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>3.523</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFA10</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit A10</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>10.495</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFA12</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit A12</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;60.713</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFA13</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit A13</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.767</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFAB1</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit AB1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;3.356</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFB3</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit B3</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.558</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFB4</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit B4</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.211</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFB5</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit B5</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;338.956</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFB6</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit B6</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.247</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFB7</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit B7</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;20.943</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFB9</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit B9</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.454</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFB10</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit B10</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.609</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFS1</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase core subunit S1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;77.83</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFS2</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase core subunit S2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;22.623</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFS3</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase core subunit S3</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;21.085</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFS5</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit S5</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.686</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFS6</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase subunit S6</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.977</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFS7</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase core subunit S7</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;69.072</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFS8</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase core subunit S8</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;45.818</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFV1</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase core subunit V1</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.552</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NDUFV2</td><td valign="top" align="left" rowspan="1" colspan="1">NADH:ubiquinone oxidoreductase core subunit V2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;5.91</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SDHA</td><td valign="top" align="left" rowspan="1" colspan="1">Succinate dehydrogenase complex flavoprotein subunit A</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.617</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SDHB</td><td valign="top" align="left" rowspan="1" colspan="1">Succinate dehydrogenase complex iron sulfur subunit B</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.018</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">UQCR10</td><td valign="top" align="left" rowspan="1" colspan="1">Ubiquinol-cytochrome c reductase, complex III subunit X</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.354</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">UQCR11</td><td valign="top" align="left" rowspan="1" colspan="1">Ubiquinol-cytochrome c reductase, complex III subunit XI</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.501</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">UQCRB</td><td valign="top" align="left" rowspan="1" colspan="1">Ubiquinol-cytochrome c reductase binding protein</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.534</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">UQCRC1</td><td valign="top" align="left" rowspan="1" colspan="1">Ubiquinol-cytochrome c reductase core protein I</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;4.993</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">UQCRC2</td><td valign="top" align="left" rowspan="1" colspan="1">Ubiquinol-cytochrome c reductase core protein II</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>373.541</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">UQCRH</td><td valign="top" align="left" rowspan="1" colspan="1">Ubiquinol-cytochrome c reductase hinge protein</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;40.845</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">UQCRQ</td><td valign="top" align="left" rowspan="1" colspan="1">Ubiquinol-cytochrome c reductase complex III subunit VII</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>9.76</bold></td></tr></tbody></table><table-wrap-foot><p><italic>Fold change of proteins detected in MCF7-MFF vs. MCF7-Control cells. Red: Up-regulated proteins; Green: Down-regulated proteins. Proteomics was performed as described in Materials and Methods. Statistical analyses were performed using ANOVA and 1.5-fold-changes in proteins with a p &#x0003c; 0.05 were considered. Dataset containing proteins with significant altered expression profile were imported into the Ingenuity Pathway Analyses (IPA) software, which groups the differentially expressed proteins into known functions and pathways</italic>.</p></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Significant changes in protein levels associated with the tricarboxylic acid cycle in MCF7 cells over-expressing mitochondrial fission factor (MFF).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Symbol</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Gene name</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Fold change</bold></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="3" rowspan="1"><bold>TCA cycle</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACO1</td><td valign="top" align="left" rowspan="1" colspan="1">Aconitase 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;33.921</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACO2</td><td valign="top" align="left" rowspan="1" colspan="1">Aconitase 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;14.648</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CS</td><td valign="top" align="left" rowspan="1" colspan="1">Citrate synthase</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;34.112</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DHTKD1</td><td valign="top" align="left" rowspan="1" colspan="1">Dehydrogenase E1 and transketolase domain containing 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;3.207</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DLD</td><td valign="top" align="left" rowspan="1" colspan="1">Dihydrolipoamide dehydrogenase</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>3.814</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DLST</td><td valign="top" align="left" rowspan="1" colspan="1">Dihydrolipoamide S-succinyltransferase</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;3.202</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FH</td><td valign="top" align="left" rowspan="1" colspan="1">Fumarate hydratase</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>14.079</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IDH1</td><td valign="top" align="left" rowspan="1" colspan="1">Isocitrate dehydrogenase [NADP(+)] 1, cytosolic</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>4.014</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IDH2</td><td valign="top" align="left" rowspan="1" colspan="1">Isocitrate dehydrogenase [NADP(+)] 2, mitochondrial</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;176.206</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IDH3A</td><td valign="top" align="left" rowspan="1" colspan="1">Isocitrate dehydrogenase 3 [NAD(+)] alpha</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;17.146</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IDH3B</td><td valign="top" align="left" rowspan="1" colspan="1">Isocitrate dehydrogenase 3 [NAD(+)] beta</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.752</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IDH3G</td><td valign="top" align="left" rowspan="1" colspan="1">Isocitrate dehydrogenase 3 [NAD(+)] gamma</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>3.159</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MDH1</td><td valign="top" align="left" rowspan="1" colspan="1">Malate dehydrogenase 1</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>24.472</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MDH2</td><td valign="top" align="left" rowspan="1" colspan="1">Malate dehydrogenase 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;211.122</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">OGDH</td><td valign="top" align="left" rowspan="1" colspan="1">Oxoglutarate dehydrogenase</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;47.17</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">OGDHL</td><td valign="top" align="left" rowspan="1" colspan="1">Oxoglutarate dehydrogenase-like</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>4.76</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SDHA</td><td valign="top" align="left" rowspan="1" colspan="1">Succinate dehydrogenase complex flavoprotein subunit A</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.617</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SDHB</td><td valign="top" align="left" rowspan="1" colspan="1">Succinate dehydrogenase complex iron sulfur subunit B</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.018</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SUCLA2</td><td valign="top" align="left" rowspan="1" colspan="1">Succinate-CoA ligase ADP-forming beta subunit</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>3.127</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SUCLG1</td><td valign="top" align="left" rowspan="1" colspan="1">Succinate-CoA ligase alpha subunit</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>6.425</bold></td></tr></tbody></table><table-wrap-foot><p><italic>Fold change of proteins detected in MCF7-MFF vs. MCF7-Control cells. Red: Up-regulated proteins; Green: Down-regulated proteins. Proteomics was performed as described in Materials and Methods. Statistical analyses were performed using ANOVA and 1.5-fold-changes in proteins with a p &#x0003c; 0.05 were considered. Dataset containing proteins with significant altered expression profile were imported into the Ingenuity Pathway Analyses (IPA) software, which groups the differentially expressed proteins into known functions and pathways</italic>.</p></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Significant changes in protein levels associated with glycolysis in MCF7 cells over-expressing mitochondrial fission factor (MFF).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Symbol</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Gene name</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Fold change</bold></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="3" rowspan="1"><bold>Glycolysis</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GLUT1</td><td valign="top" align="left" rowspan="1" colspan="1">Facilitated glucose transporter member 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;27.22</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HXK1</td><td valign="top" align="left" rowspan="1" colspan="1">Hexokinase 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;17.96</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HXK2</td><td valign="top" align="left" rowspan="1" colspan="1">Hexokinase 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02013;Infinity</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HXK3</td><td valign="top" align="left" rowspan="1" colspan="1">Hexokinase 3</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.755</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ALDOA</td><td valign="top" align="left" rowspan="1" colspan="1">Aldolase, fructose-bisphosphate A</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;63.01</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ALDOC</td><td valign="top" align="left" rowspan="1" colspan="1">Aldolase, fructose-bisphosphate C</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>3.304</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ENO1</td><td valign="top" align="left" rowspan="1" colspan="1">Enolase 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;353.572</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ENO2</td><td valign="top" align="left" rowspan="1" colspan="1">Enolase 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;14.088</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ENO3</td><td valign="top" align="left" rowspan="1" colspan="1">Enolase 3</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>4.658</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FBP1</td><td valign="top" align="left" rowspan="1" colspan="1">Fructose-bisphosphatase 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;5.137</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GAPDH</td><td valign="top" align="left" rowspan="1" colspan="1">Glyceraldehyde-3-phosphate dehydrogenase</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>37.238</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GPI</td><td valign="top" align="left" rowspan="1" colspan="1">Glucose-6-phosphate isomerase</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>3.486</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PFKM</td><td valign="top" align="left" rowspan="1" colspan="1">Phosphofructokinase, muscle</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;5.855</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PFKP</td><td valign="top" align="left" rowspan="1" colspan="1">Phosphofructokinase, platelet</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02013;Infinity</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PGAM1</td><td valign="top" align="left" rowspan="1" colspan="1">Phosphoglycerate mutase 1</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>3.86</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PGAM4</td><td valign="top" align="left" rowspan="1" colspan="1">Phosphoglycerate mutase family member 4</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.668</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PGK1</td><td valign="top" align="left" rowspan="1" colspan="1">Phosphoglycerate kinase 1</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>250.959</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PGK2</td><td valign="top" align="left" rowspan="1" colspan="1">Phosphoglycerate kinase 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;28.097</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PKLR</td><td valign="top" align="left" rowspan="1" colspan="1">Pyruvate kinase, liver and RBC</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;11.843</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PKM</td><td valign="top" align="left" rowspan="1" colspan="1">Pyruvate kinase, muscle</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;92.492</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TPI1</td><td valign="top" align="left" rowspan="1" colspan="1">Triosephosphate isomerase 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;44.171</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LDHA</td><td valign="top" align="left" rowspan="1" colspan="1">Lactate dehydrogenase A</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.82</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LDHA6LB</td><td valign="top" align="left" rowspan="1" colspan="1">Lactate dehydrogenase A like 6B</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;58.176</bold></td></tr></tbody></table><table-wrap-foot><p><italic>Fold change of proteins detected in MCF7-MFF vs. MCF7-Control cells. Red: Up-regulated proteins; Green: Down-regulated proteins. Proteomics was performed as described in Materials and Methods. Statistical analyses were performed using ANOVA and 1.5-fold-changes in proteins with a p &#x0003c; 0.05 were considered. Dataset containing proteins with significant altered expression profile were imported into the Ingenuity Pathway Analyses (IPA) software, which groups the differentially expressed proteins into known functions and pathways</italic>.</p></table-wrap-foot></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Significant changes in protein levels associated with the pentose phosphate pathway in MCF7 cells overexpressing mitochondrial fission factor (MFF).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Symbol</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Gene name</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Fold change</bold></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="3" rowspan="1"><bold>Pentose phosphate pathway</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">G6PD</td><td valign="top" align="left" rowspan="1" colspan="1">Glucose-6-phosphate dehydrogenase</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;136.908</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PGD</td><td valign="top" align="left" rowspan="1" colspan="1">Phosphogluconate dehydrogenase</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>4.903</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PGLS</td><td valign="top" align="left" rowspan="1" colspan="1">6-phosphogluconolactonase</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.776</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RPE</td><td valign="top" align="left" rowspan="1" colspan="1">Ribulose-5-phosphate-3-epimerase</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.25</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RPIA</td><td valign="top" align="left" rowspan="1" colspan="1">Ribose 5-phosphate isomerase A</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;11.28</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TALDO1</td><td valign="top" align="left" rowspan="1" colspan="1">Transaldolase 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;6.741</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TKT</td><td valign="top" align="left" rowspan="1" colspan="1">Transketolase</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;82.993</bold></td></tr></tbody></table><table-wrap-foot><p><italic>Fold change of proteins detected in MCF7-MFF vs. MCF7-Control cells. Red: Up-regulated proteins; Green: Down-regulated proteins. Proteomics was performed as described in Materials and Methods. Statistical analyses were performed using ANOVA and 1.5-fold-changes in proteins with a p &#x0003c; 0.05 were considered. Dataset containing proteins with significant altered expression profile were imported into the Ingenuity Pathway Analyses (IPA) software, which groups the differentially expressed proteins into known functions and pathways</italic>.</p></table-wrap-foot></table-wrap><fig id="F5" position="float"><label>Figure 5</label><caption><p>Precursors of metabolism list. Precursor of metabolism list enriched by the proteins significantly regulated in MCF7 harboring mitochondrial fission factor (MFF) compared to MCF7 Control cells. The list has been generated by Ingenuity Pathway Analysis (IPA). The <italic>p</italic>-value for each pathway is represented by the height of the bars and is expressed as &#x02212;1 times the log of the <italic>p</italic>-value. The orange dotted line represents the threshold of <italic>p</italic> = 0.05 as calculated by Fischer's test and denotes the cut-off for significance.</p></caption><graphic xlink:href="fonc-10-01776-g0005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><p>Toxicological Pathways and Functions significantly regulated in MCF7 cells overexpressing the mitochondrial fission factor (MFF). Toxicity list enriched by the proteins significantly regulated in MCF7 harboring mitochondrial fission factor (MFF) has been generated by Ingenuity Pathway Analysis (IPA). The <italic>p</italic>-value for each pathway is represented by the height of the bars and is expressed as &#x02212;1 times the log of the <italic>p</italic>-value. The orange dotted line represents the threshold of <italic>p</italic> = 0.05 as calculated by Fischer's test and denotes the cut-off for significance.</p></caption><graphic xlink:href="fonc-10-01776-g0006"/></fig></sec><sec><title>Signaling Pathways and Predicted Biological Responses</title><p>To interrogate how MFF over-expression would trigger the activation of specific intracellular signaling cascades, which are predicted to control distinct biological responses, a dataset containing proteins with significant altered expression profile was imported into the IPA tool. As shown in <xref ref-type="fig" rid="F7">Figure 7</xref>, the most strongly differentially activated pathways in MCF7-MFF cells are predicted to regulate EI2F signaling, as well as epithelial adherens junctions and the cytoskeleton. Accordingly, down-regulation of proteins involved in Epithelial Mesenchymal Transition (EMT), Extracellular Matrix (ECM) and cytoskeleton remodeling is detected in MCF-MFF cells (<xref rid="T6" ref-type="table">Table 6</xref>). In addition, proteins involved in metastasis formation (MTA1 and MTA2), oxidative stress signaling (CAT, SOD2, TXNRD1, GLRX3, GSR, TXNL1, TXNRD2, TXNRD3), TGF&#x000df; pathway (TGFB1, TGFBR3, TGFIF2lX, STAT1, STAT3) and TNF-alpha (TNFRSF12A, TRAF2) were all dramatically down-regulated in MCF7-MFF cells (<xref rid="T7" ref-type="table">Table 7</xref>). In order to further characterize the signaling landscape of MCF7-MFF cells, we performed a Regulator-Effects analysis, which integrates and merges together Upstream Regulator Networks with Downstream Effect Networks, thereby deriving how predicted regulators might impact biological processes. As shown in <xref ref-type="fig" rid="F8">Figure 8</xref>, inhibition of cell adhesion and survival (A), and activation of cell death response (B) are the main biological events associated with MFF over-expression. The identification of the signaling mediators potentially linking upstream mediators with down-stream effects is also shown. Taken together, these data suggest that aberrant mitochondrial fragmentation may halt breast cancer cell survival and activate cell death programs by regulating a number of effectors also involved in ECM remodeling, the oxidative stress response, and mitochondrial metabolic function.</p><fig id="F7" position="float"><label>Figure 7</label><caption><p>Canonical pathways enriched in proteins differentially regulated in MCF7 cells overexpressing the mitochondrial fission factor (MFF). Significant canonical pathways associated to cell signaling were generated by Ingenuity Pathway Analysis (IPA). X axis represents pathways and Y axis represents &#x02013;log (<italic>p</italic>-value) calculated with Fisher's exact test. A <italic>p</italic>-value threshold of 0.05 is applied and is represented by the orange dotted line.</p></caption><graphic xlink:href="fonc-10-01776-g0007"/></fig><table-wrap id="T6" position="float"><label>Table 6</label><caption><p>Significant changes in protein levels associated with the epithelial-mesenchymal transition (EMT), extracellular matrix and cytoskeleton in MCF7 cells over-expressing mitochondrial fission factor (MFF).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Symbol</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Gene name</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Fold change</bold></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="3" rowspan="1"><bold>Epithelial-mesenchymal transition, ECM and cytoskeleton proteins</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VIM</td><td valign="top" align="left" rowspan="1" colspan="1">Vimentin</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;122.836</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACTA2</td><td valign="top" align="left" rowspan="1" colspan="1">Actin, alpha 2, smooth muscle, aorta</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;1.639</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TNC</td><td valign="top" align="left" rowspan="1" colspan="1">Tenascin C</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;18.294</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CNN2</td><td valign="top" align="left" rowspan="1" colspan="1">Calponin 2</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>109.554</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CALU</td><td valign="top" align="left" rowspan="1" colspan="1">Calumenin</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>9.943</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CAND1</td><td valign="top" align="left" rowspan="1" colspan="1">Cullin associated and neddylation dissociated 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;50.592</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CANX</td><td valign="top" align="left" rowspan="1" colspan="1">Calnexin</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>289.77</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CFL1</td><td valign="top" align="left" rowspan="1" colspan="1">Cofilin 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;4.993</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CTNNA1</td><td valign="top" align="left" rowspan="1" colspan="1">Catenin alpha 1</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>15.851</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CTNNA2</td><td valign="top" align="left" rowspan="1" colspan="1">Catenin alpha 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;46.852</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CTNND1</td><td valign="top" align="left" rowspan="1" colspan="1">Catenin delta 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;50.914</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSN</td><td valign="top" align="left" rowspan="1" colspan="1">Gelsolin</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;9.378</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KTN1</td><td valign="top" align="left" rowspan="1" colspan="1">Kinectin 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;27.16</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VCL</td><td valign="top" align="left" rowspan="1" colspan="1">Vinculin</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.965</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">THBS1</td><td valign="top" align="left" rowspan="1" colspan="1">Thrombospondin 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;26.041</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TAGLN2</td><td valign="top" align="left" rowspan="1" colspan="1">Transgelin 2</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>3.578</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TAGLN3</td><td valign="top" align="left" rowspan="1" colspan="1">Transgelin 3</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;18.464</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CUL1</td><td valign="top" align="left" rowspan="1" colspan="1">Cullin 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;24.7</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CUL2</td><td valign="top" align="left" rowspan="1" colspan="1">Cullin 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;3.6</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CUL3</td><td valign="top" align="left" rowspan="1" colspan="1">Cullin 3</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;43.342</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CUL7</td><td valign="top" align="left" rowspan="1" colspan="1">Cullin 7</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;24.685</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CUL4A</td><td valign="top" align="left" rowspan="1" colspan="1">Cullin 4A</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;4.282</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CUL4B</td><td valign="top" align="left" rowspan="1" colspan="1">Cullin 4B</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;30.196</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DES</td><td valign="top" align="left" rowspan="1" colspan="1">Desmin</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;2.734</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COL11A1</td><td valign="top" align="left" rowspan="1" colspan="1">Collagen type XI alpha 1 chain</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;156.421</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COL28A1</td><td valign="top" align="left" rowspan="1" colspan="1">Collagen type XXVIII alpha 1 chain</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;65.077</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COL2A1</td><td valign="top" align="left" rowspan="1" colspan="1">Collagen type II alpha 1 chain</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;110.781</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COL8A1</td><td valign="top" align="left" rowspan="1" colspan="1">Collagen type VIII alpha 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;7.542</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACTB</td><td valign="top" align="left" rowspan="1" colspan="1">Actin beta</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;378.155</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACTBL2</td><td valign="top" align="left" rowspan="1" colspan="1">Actin, beta like 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;100.94</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACTC1</td><td valign="top" align="left" rowspan="1" colspan="1">Actin, alpha, cardiac muscle 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;101.765</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACTG1</td><td valign="top" align="left" rowspan="1" colspan="1">Actin gamma 1</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>4.483</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACTN1</td><td valign="top" align="left" rowspan="1" colspan="1">Actinin alpha 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;4.133</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACTN2</td><td valign="top" align="left" rowspan="1" colspan="1">Actinin alpha 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;2.295</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACT</td><td valign="top" align="left" rowspan="1" colspan="1">Actin-like protein (ACT) gene</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;20.682</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACTG1P4</td><td valign="top" align="left" rowspan="1" colspan="1">Actin gamma 1 pseudogene 4</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;2.329</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACTN4</td><td valign="top" align="left" rowspan="1" colspan="1">Actinin alpha 4</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>30.372</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MYH9</td><td valign="top" align="left" rowspan="1" colspan="1">Myosin, heavy chain 9, non-muscle</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>820.527</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MYH10</td><td valign="top" align="left" rowspan="1" colspan="1">Myosin, heavy chain 10, non-muscle</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>7.969</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MYH11</td><td valign="top" align="left" rowspan="1" colspan="1">Myosin heavy chain 11</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;46.952</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MYH7B</td><td valign="top" align="left" rowspan="1" colspan="1">Myosin heavy chain 7B</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;13.017</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MYL1</td><td valign="top" align="left" rowspan="1" colspan="1">Myosin light chain 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;10.816</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MYL6</td><td valign="top" align="left" rowspan="1" colspan="1">Myosin light chain 6</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.94</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MYL12A</td><td valign="top" align="left" rowspan="1" colspan="1">Myosin light chain 12A</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.173</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MYL6B</td><td valign="top" align="left" rowspan="1" colspan="1">Myosin light chain 6B</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02013;Infinity</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MYO1B</td><td valign="top" align="left" rowspan="1" colspan="1">Myosin IB</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.551</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MYO1C</td><td valign="top" align="left" rowspan="1" colspan="1">Myosin IC</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;51.931</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBA8</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin alpha 8</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;15.245</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBA1A</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin alpha 1a</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.545</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBA3E</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin alpha 3e</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.5</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBA4A</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin alpha 4a</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;22.152</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBAL3</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin alpha like 3</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;3.393</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBB3</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin beta 3 class III</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;3.965</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBB6</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin beta 6 class V</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;18.369</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBB8</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin beta 8 class VIII</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.78</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBB2A</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin beta 2A class IIa</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;2.783</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBB2B</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin beta 2B class IIb</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.353</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBB4A</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin beta 4A class IVa</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.216</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBGCP2</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin gamma complex associated protein 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02013;Infinity</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBGCP6</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin gamma complex associated protein 6</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02013;Infinity</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBA1B</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin alpha 1b</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;5.529</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBA1C</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin alpha 1c</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;11.125</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBB</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin beta class I</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;90.993</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TUBB4B</td><td valign="top" align="left" rowspan="1" colspan="1">Tubulin beta 4B class IVb</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;25.109</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNM1</td><td valign="top" align="left" rowspan="1" colspan="1">Dynamin 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;20.927</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNM2</td><td valign="top" align="left" rowspan="1" colspan="1">Dynamin 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;18.654</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNM3</td><td valign="top" align="left" rowspan="1" colspan="1">Dynamin 3</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;9.012</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNMBP</td><td valign="top" align="left" rowspan="1" colspan="1">Dynamin binding protein</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;4.552</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LAMA3</td><td valign="top" align="left" rowspan="1" colspan="1">Laminin subunit alpha 3</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;58.838</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LAMB2</td><td valign="top" align="left" rowspan="1" colspan="1">Laminin subunit beta 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;12.831</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LAMB3</td><td valign="top" align="left" rowspan="1" colspan="1">Laminin subunit beta 3</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;77.639</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LAMB4</td><td valign="top" align="left" rowspan="1" colspan="1">Laminin subunit beta 4</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;8.215</bold></td></tr></tbody></table><table-wrap-foot><p><italic>Fold change of proteins detected in MCF7-MFF vs. MCF7-Control cells. Red: Up-regulated proteins; Green: Down-regulated proteins. Proteomics was performed as described in Materials and Methods. Statistical analyses were performed using ANOVA and 1.5-fold-changes in proteins with a p &#x0003c; 0.05 were considered. Dataset containing proteins with significant altered expression profile were imported into the Ingenuity Pathway Analyses (IPA) software, which groups the differentially expressed proteins into known functions and pathways</italic>.</p></table-wrap-foot></table-wrap><table-wrap id="T7" position="float"><label>Table 7</label><caption><p>Significant changes in other protein levels in MCF7 cells over-expressing mitochondrial fission factor (MFF).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Symbol</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Gene name</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Fold change</bold></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="3" rowspan="1"><bold>Other proteins</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MTA1</td><td valign="top" align="left" rowspan="1" colspan="1">Metastasis associated 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;41.671</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MTA2</td><td valign="top" align="left" rowspan="1" colspan="1">Metastasis associated 1 family member 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;17.064</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MTSS1L</td><td valign="top" align="left" rowspan="1" colspan="1">Metastasis suppressor 1 like</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.028</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">UCP3</td><td valign="top" align="left" rowspan="1" colspan="1">Uncoupling protein 3</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;62.533</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TIGAR</td><td valign="top" align="left" rowspan="1" colspan="1">TP53 induced glycolysis regulatory phosphatase</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;39.761</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TGFBI</td><td valign="top" align="left" rowspan="1" colspan="1">Transforming growth factor beta induced</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02013;Infinity</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TGFBR3</td><td valign="top" align="left" rowspan="1" colspan="1">Transforming growth factor beta receptor 3</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;8.57</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TGIF2LX</td><td valign="top" align="left" rowspan="1" colspan="1">TGFB induced factor homeobox 2 like, X-linked</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;12.818</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">STAT1</td><td valign="top" align="left" rowspan="1" colspan="1">Signal transducer and activator of transcription 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;9.228</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">STAT3</td><td valign="top" align="left" rowspan="1" colspan="1">Signal transducer and activator of transcription 3</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;7.953</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">OXSR1</td><td valign="top" align="left" rowspan="1" colspan="1">Oxidative stress responsive 1</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>6.331</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PCNA</td><td valign="top" align="left" rowspan="1" colspan="1">Proliferating cell nuclear antigen</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>3.128</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HSF1</td><td valign="top" align="left" rowspan="1" colspan="1">Heat shock transcription factor 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;28.884</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TRAP1</td><td valign="top" align="left" rowspan="1" colspan="1">TNF receptor associated protein 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;10.989</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CAT</td><td valign="top" align="left" rowspan="1" colspan="1">Catalase</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;10.918</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SOD2</td><td valign="top" align="left" rowspan="1" colspan="1">Superoxide dismutase 2, mitochondrial</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;33.389</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TXNRD1</td><td valign="top" align="left" rowspan="1" colspan="1">Thioredoxin reductase 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;21.824</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GLRX3</td><td valign="top" align="left" rowspan="1" colspan="1">Glutaredoxin 3</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;1.845</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSR</td><td valign="top" align="left" rowspan="1" colspan="1">Glutathione-disulfide reductase</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;1E+08</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSS</td><td valign="top" align="left" rowspan="1" colspan="1">Glutathione synthetase</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.547</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GSTM3</td><td valign="top" align="left" rowspan="1" colspan="1">Glutathione S-transferase mu 3</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>18.065</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ROMO1</td><td valign="top" align="left" rowspan="1" colspan="1">Reactive oxygen species modulator 1</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.966</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SMAD9</td><td valign="top" align="left" rowspan="1" colspan="1">SMAD family member 9</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;1.975</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TXNL1</td><td valign="top" align="left" rowspan="1" colspan="1">Thioredoxin like 1</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;9.869</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TXNRD2</td><td valign="top" align="left" rowspan="1" colspan="1">Thioredoxin reductase 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;3.538</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TXNRD3</td><td valign="top" align="left" rowspan="1" colspan="1">Thioredoxin reductase 3</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02013;Infinity</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TMX1</td><td valign="top" align="left" rowspan="1" colspan="1">Thioredoxin related transmembrane protein 1</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>3.142</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TMX4</td><td valign="top" align="left" rowspan="1" colspan="1">Thioredoxin related transmembrane protein 4</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>1.518</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TNFRSF12A</td><td valign="top" align="left" rowspan="1" colspan="1">TNF receptor superfamily member 12A</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02013;Infinity</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TNFSF13B</td><td valign="top" align="left" rowspan="1" colspan="1">Tumor necrosis factor superfamily member 13b</td><td valign="top" align="center" style="color:#ff002f" rowspan="1" colspan="1"><bold>2.397</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TRAF2</td><td valign="top" align="left" rowspan="1" colspan="1">TNF receptor associated factor 2</td><td valign="top" align="center" style="color:#23a657" rowspan="1" colspan="1"><bold>&#x02212;7.759</bold></td></tr></tbody></table><table-wrap-foot><p><italic>Fold change of proteins detected in MCF7-MFF vs. MCF7-Control cells. Red: Up-regulated proteins; Green: Down-regulated proteins. Note down-regulation of relevant proteins involved in the metastatic process and oxidative stress response. Proteomics was performed as described in Materials and Methods. Statistical analyses were performed using ANOVA and 1.5-fold-changes in proteins with a p &#x0003c; 0.05 were considered. Dataset containing proteins with significant altered expression profile were imported into the Ingenuity Pathway Analyses (IPA) software, which groups the differentially expressed proteins into known functions and pathways</italic>.</p></table-wrap-foot></table-wrap><fig id="F8" position="float"><label>Figure 8</label><caption><p>Regulator effect networks generated by Ingenuity Pathway Analysis (IPA) in MCF7 over-expressed mitochondrial fission factor (MFF). IPA analysis generated several regulator effect networks in MCF7 cells over-expressing mitochondrial fission factor (MFF). Both upstream regulators and downstream cellular responses were identified in relation to certain proteins significantly altered in our dataset. Upstream regulators are shown at the top while functions and phenotypes are displayed at the bottom. Significantly regulated proteins connecting the upper and lower panel are displayed in the middle. Red and green colors represent significant up/down-regulation, respectively, with the intensity of the color reflecting the degree of change. Orange color predicts an overall activation of the pathway while blue indicates a prediction of an overall decrease based on z-score value. Inconsistent relationships are represented as yellow line. Note that in MCF7 harboring MFF some of the proteins in our dataset have been predicted to be inhibited by the upstream regulators ERG, LGALS3, and MYC leading to an overall inhibition (blue) of cell survival and/or activation (orange) of cell death. <bold>(A)</bold> Cell survival and adhesion; <bold>(B)</bold> Cell death.</p></caption><graphic xlink:href="fonc-10-01776-g0008"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Here, we have generated a mitochondrial fission factor (MFF)-overexpressing breast cancer cell line in order to dissect the role of aberrant mitochondrial fission in the maintenance and dissemination of breast CSCs. We have found that MFF overexpression inhibits mitochondrial biogenesis and oxidative metabolism, depleting intracellular ATP levels. Furthermore, MFF-overexpressing breast cancer cells exhibit a reduction in stemness properties, as evidenced by the inhibition of 3D mammosphere formation capacity and decreases in the stem cell marker ALDH. Consistent with these observations, proteomic analysis performed in MFF-overexpressing breast cancer cells predicted a proteomic signature associated with the inhibition of mitochondrial function, and a metabolically quiescent cell phenotype, as well as the inhibition of cancer cell survival and the increase of cell death.</p><p>Mitochondria, which have classically been considered as the cell's &#x0201c;power-house,&#x0201d; extract energy from oxidative phosphorylation to efficiently support tumor growth (<xref rid="B1" ref-type="bibr">1</xref>). Despite their unquestionable role in generating ATP from multiple fuels, mitochondria are now considered as central hubs which drive important tumor traits. For instance, mitochondria have been implicated in metastasis formation and spreading to distant sites, as well as drug resistance (<xref rid="B18" ref-type="bibr">18</xref>). In addition, mitochondria have been shown to support the survival of dormant tumor cells after oncogene ablation, thus promoting disease relapse (<xref rid="B32" ref-type="bibr">32</xref>). Many of these actions attributed to mitochondria have been correlated with the impact that these organelles exert on the biology of CSCs (<xref rid="B33" ref-type="bibr">33</xref>). Several lines of evidence have suggested that mitochondria support stem cell traits, thus facilitating self-renewal and resistance to differentiation (<xref rid="B2" ref-type="bibr">2</xref>). For instance, a strict reliance on young, viable and competent mitochondria is required during asymmetric cell division; in fact, older and aged mitochondria are clustered within daughter cells committed to differentiation, whereas &#x0201c;newly synthesized&#x0201d; and younger mitochondria are apportioned within daughter cells that retain a stem-like phenotype (<xref rid="B34" ref-type="bibr">34</xref>).</p><p>As the relationship between the mitochondrial-dependent bioenergetic responses and the CSC metabolic profile has been explored, it's not surprising that a mitochondria-centric regulation of cancer energy pathways can drive complex decision-making events, ultimately impacting CSC fate toward tumor progression. As a consequence of these findings, synthetic as well as natural compounds that impair mitochondrial function have been shown to selectively hamper CSC propagation in diverse tumor types (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B35" ref-type="bibr">35</xref>&#x02013;<xref rid="B38" ref-type="bibr">38</xref>). Interestingly, as mitochondria evolutionary derive from the engulfment of an &#x003b1;-proteobacterium in eukaryotic host cells, several classes of FDA-approved antibiotics have been suggested in a repurposing effort for the selective targeting of mitochondria (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B39" ref-type="bibr">39</xref>). The most remarkable of these repurposing strategies is represented by the antibiotic Doxycycline, a relatively manageable and safe tetracycline analog, which inhibits CSC dissemination <italic>in vitro</italic>, by targeting mitochondria biogenesis, as well as mitochondrial-dependent bioenergetic metabolism (<xref rid="B11" ref-type="bibr">11</xref>). Of note, a Phase II clinical trial performed in early breast cancer patients, using the oral administration of Doxycycline, was sufficient to selective reduce the stemness markers ALDH1 and CD44 (<xref rid="B9" ref-type="bibr">9</xref>). These studies pave the way for further exploring the role of mitochondria in cancer, and the investigation of novel mitochondrial-based druggable targets to be exploited as anti-cancer strategies.</p><p>Mitochondrial fission and fusion dynamics play an integral role in the complex regulation of mitochondrial function (<xref rid="B25" ref-type="bibr">25</xref>). Fragmentation and fusion are tightly balanced processes which probably derive from the same endowment mechanisms through which bacteria were co-opted into host cells. As such, it's not surprising that alterations in fusion/fission balance may play a key role in the pathogenesis of several diseases, including cancer (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B25" ref-type="bibr">25</xref>).</p><p>Our data show that in breast cancer enhanced mitochondrial fragmentation reduces mitochondrial mass and membrane potential, suggesting that aberrant fission may compromise the efficiency of the energetic cell machinery. Mechanistically, this model could be explained by the bi-directional link existing between mitochondrial morphology and redox homeostasis. In fact, pro-fission programs leading to mitochondrial fragmentation have been shown to stimulate ROS production (<xref rid="B40" ref-type="bibr">40</xref>); furthermore, the activation of mitochondrial fission was required to generate ROS during hyperglycemic conditions (<xref rid="B41" ref-type="bibr">41</xref>), thereby suggesting that unopposed mitochondrial fragmentation is associated with enhanced ROS production and compromission of the energetic machinery.</p><p>Indeed, analysis of metabolic flux showed that in MFF-overexpressing breast cancer cells the capability to extract ATP from energetic sources is compromised. These data are in accordance with previous studies showing that natural or synthetic compounds that block mitochondrial biogenesis and thereby reduce mitochondrial mass, also interfere with mitochondrial energetic function [reviewed in (<xref rid="B8" ref-type="bibr">8</xref>)]. Likewise, the metabolic effects of abnormal mitochondrial fission may parallel the biochemical responses observed in breast cancer cells treated with mitochondrial-targeting agents. Our data from proteomic analyses provide supporting evidence that MFF over-expression mainly drives the acquisition of a metabolically suppressed cell phenotype, as demonstrated by the drastic reduction of proteins involved in several energetic pathways in MCF7-MFF vs. MCF7-Control cells. Therefore, unopposed mitochondrial fragmentation induces mitochondrial dysfunction, leading to the inability to extract ATP from fuels and an overall block in cell metabolism.</p><p>As cancer cells are strictly dependent on active energetic cellular machinery for their survival, any alteration in mitochondrial integrity may compromise cancer cell viability (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>). The proteomic analyses performed in MFF-overexpressing breast cancer cells showed that enhanced mitochondrial fission is associated not only with loss of mitochondrial proteins, impaired ability to cope with oxidative stress, and reduced metabolic function, but also with a quiescent cell phenotype. More specifically, the proteomic landscape of MFF over-expressing breast cancer cells highlights a clear inhibition of proteins involved in cell adhesion and cell junction, together with the inhibition of the EMT program, and metastasis-related mediators. Furthermore, our proteomic analysis predicts a substantial inhibition of cell survival pathways and the activation of cell death programs, consistent with a metabolically suppressed cell phenotype.</p><p>These data are in accordance with previous studies showing that MFF-dependent mitochondrial fission activates signaling pathways involved in the inhibition of cell viability and the activation of the apoptotic response (<xref rid="B44" ref-type="bibr">44</xref>). In particular, MFF and other mediators involved in mitochondrial fragmentation such as DRP1 play an integral role in cancer cell death in response to diverse stimuli, including several anticancer drugs (<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B46" ref-type="bibr">46</xref>). At least some of these effects could be attributed to the generation of mitochondrial ROS, which would thereafter trigger apoptotic cell death (<xref rid="B47" ref-type="bibr">47</xref>).</p><p>Mitochondrial proteins are overexpressed in CSCs, which also exhibit increased mitochondrial metabolic function (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B7" ref-type="bibr">7</xref>). Indeed, tracking mitochondrial mass represents an important metabolic tool to identify an enrichment of CSCs (<xref rid="B7" ref-type="bibr">7</xref>). Due to these unusual features, CSCs are selectively targeted by a number of mitochondria impairing agents, which have been shown to compromise mitochondrial function and thereafter halt CSC propagation (<xref rid="B8" ref-type="bibr">8</xref>). Likewise, in the present study we have shown that mitochondrial-driven impairment in metabolic function is associated with the loss of stemness features in MFF over-expressing breast cancer cells. These observations indicate that uncontrolled mitochondrial fission may drive the acquisition of an inactive metabolic phenotype associated with the starvation of the CSCs population. Therefore, the pharmacological manipulation of mitochondrial fission may serve as an actionable tool to eradicate cancer cells, with tumor initiating capabilities. Accordingly, it has been recently shown that an MFF peptidomimetic strategy elicits anti-cancer activity in patient-derived xenografts, primary breast and lung adenocarcinoma 3D organoids, as well as glioblastoma neurospheres (<xref rid="B45" ref-type="bibr">45</xref>).</p><p>Recently, drugs targeting mitochondrial dynamics are beginning to emerge as novel strategies in cancer treatment. It should be mentioned that their potential is still challenged by several controversies and awaits further confirmation. For instance, the inhibitor of mitochondrial fission named mdiv-1, which acts as a Drp1 GTPase activity inhibitor, can cause a loss of the functional properties of CSCs (<xref rid="B48" ref-type="bibr">48</xref>). However, this drug appears to also work as a reversible inhibitor of mitochondrial complex I, leading to alterations of mitochondrial ROS production (<xref rid="B49" ref-type="bibr">49</xref>). Additional layers of complexity have to be considered when exploring the contribution of mitochondrial shaping genes in tumor biology. Indeed, tumor microevironmental conditions; the presence of hormonal/growth factors; and intrinsic features of the specific tumor cell types involved may affect mitodynamics pathways.</p><p>In conclusion, the data presented herein validate the use of a mitodynamic approach to target mitochondria architecture and function toward the eradication of CSCs. Further studies will be necessary to validate the use of this therapeutic strategy, especially in combination with additional metabolic inhibitors as novel tools to control stem traits in cancer.</p></sec><sec sec-type="data-availability" id="s5"><title>Data Availability Statement</title><p>The datasets generated for this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found here: ProteomeXchange via PRIDE dataset (identifier: PXD020802).</p></sec><sec id="s6"><title>Author Contributions</title><p>ML and FS conceived and initiated this project. All experiments described in this paper were performed by RS-A. MF performed the 3D mammosphere assays. ED wrote the manuscript with input from RS-A. ML and FS edited the manuscript. All authors contributed to the article and approved the submitted version.</p></sec><sec id="s7"><title>Conflict of Interest</title><p>ML and FS hold a minority interest in Lunella Biotech, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>We are grateful to Rumana Rafiq, for her kind and dedicated assistance, in keeping the Translational Medicine Laboratory at Salford running very smoothly. We would like to thank the Foxpoint Foundation and the Healthy Life Foundation for their philanthropic donations toward new equipment and infrastructure, in the Translational Medicine Laboratory, at the University of Salford.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was supported by research grant funding, provided by Lunella Biotech, Inc. (to FS and ML).</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vyas</surname><given-names>S</given-names></name><name><surname>Zaganjor</surname><given-names>E</given-names></name><name><surname>Haigis</surname><given-names>MC</given-names></name></person-group>. <article-title>Mitochondria and cancer</article-title>. <source>Cell.</source> (<year>2016</year>) <volume>166</volume>:<fpage>555</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.07.002</pub-id><pub-id pub-id-type="pmid">27471965</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>M-K</given-names></name><name><surname>Cheong</surname><given-names>J-H</given-names></name></person-group>. <article-title>Mitochondria-centric bioenergetic characteristics in cancer stem-like cells</article-title>. <source>Arch Pharm Res.</source> (<year>2019</year>) <volume>42</volume>:<fpage>113</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1007/s12272-019-01127-y</pub-id><pub-id pub-id-type="pmid">30771209</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris-Pag&#x000e8;s</surname><given-names>M</given-names></name><name><surname>Martinez-Outschoorn</surname><given-names>UE</given-names></name><name><surname>Pestell</surname><given-names>RG</given-names></name><name><surname>Sotgia</surname><given-names>F</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name></person-group>. <article-title>Cancer stem cell metabolism</article-title>. <source>Breast Cancer Res.</source> (<year>2016</year>) <volume>18</volume>:<fpage>55</fpage>. <pub-id pub-id-type="doi">10.1186/s13058-016-0712-6</pub-id><pub-id pub-id-type="pmid">27220421</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visvader</surname><given-names>JE</given-names></name></person-group>. <article-title>Cells of origin in cancer</article-title>. <source>Nature.</source> (<year>2011</year>) <volume>469</volume>:<fpage>314</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1038/nature09781</pub-id><pub-id pub-id-type="pmid">21248838</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farnie</surname><given-names>G</given-names></name><name><surname>Sotgia</surname><given-names>F</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name></person-group>. <article-title>High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant</article-title>. <source>Oncotarget.</source> (<year>2015</year>) <volume>6</volume>:<fpage>30472</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.5401</pub-id><pub-id pub-id-type="pmid">26421710</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>R</given-names></name><name><surname>Ozsvari</surname><given-names>B</given-names></name><name><surname>Bonuccelli</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Pestell</surname><given-names>RG</given-names></name><name><surname>Martinez-Outschoorn</surname><given-names>UE</given-names></name><etal/></person-group>. <article-title>Dissecting tumor metabolic heterogeneity: telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells</article-title>. <source>Oncotarget.</source> (<year>2015</year>) <volume>6</volume>:<fpage>21892</fpage>&#x02013;<lpage>905</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.5260</pub-id><pub-id pub-id-type="pmid">26323205</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>R</given-names></name><name><surname>Bonuccelli</surname><given-names>G</given-names></name><name><surname>Ozsv&#x000e1;ri</surname><given-names>B</given-names></name><name><surname>Peiris-Pag&#x000e8;s</surname><given-names>M</given-names></name><name><surname>Fiorillo</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><etal/></person-group>. <article-title>Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: understanding WNT/FGF-driven anabolic signaling</article-title>. <source>Oncotarget.</source> (<year>2015</year>) <volume>6</volume>:<fpage>30453</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.5852</pub-id><pub-id pub-id-type="pmid">26421711</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Francesco</surname><given-names>EM</given-names></name><name><surname>Sotgia</surname><given-names>F</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name></person-group>. <article-title>Cancer stem cells (CSCs): metabolic strategies for their identification and eradication</article-title>. <source>Biochem J.</source> (<year>2018</year>) <volume>475</volume>:<fpage>1611</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1042/BCJ20170164</pub-id><pub-id pub-id-type="pmid">29743249</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scatena</surname><given-names>C</given-names></name><name><surname>Roncella</surname><given-names>M</given-names></name><name><surname>Di Paolo</surname><given-names>A</given-names></name><name><surname>Aretini</surname><given-names>P</given-names></name><name><surname>Menicagli</surname><given-names>M</given-names></name><name><surname>Fanelli</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Doxycycline, an inhibitor of mitochondrial biogenesis, effectively reduces Cancer Stem Cells (CSCs) in early breast cancer patients: a clinical pilot study</article-title>. <source>Front Oncol.</source> (<year>2018</year>) <volume>8</volume>:<fpage>452</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2018.00452</pub-id><pub-id pub-id-type="pmid">30364293</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris-Pag&#x000e8;s</surname><given-names>M</given-names></name><name><surname>Sotgia</surname><given-names>F</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name></person-group>. <article-title>Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose</article-title>. <source>Oncoscience.</source> (<year>2015</year>) <volume>2</volume>:<fpage>696</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.18632/oncoscience.215</pub-id><pub-id pub-id-type="pmid">26425660</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>R</given-names></name><name><surname>Fiorillo</surname><given-names>M</given-names></name><name><surname>Chadwick</surname><given-names>A</given-names></name><name><surname>Ozsvari</surname><given-names>B</given-names></name><name><surname>Reeves</surname><given-names>KJ</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><etal/></person-group>. <article-title>Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: implications for more effective radiation therapy</article-title>. <source>Oncotarget.</source> (<year>2015</year>) <volume>6</volume>:<fpage>14005</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.4159</pub-id><pub-id pub-id-type="pmid">26087309</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>R</given-names></name><name><surname>Ozsvari</surname><given-names>B</given-names></name><name><surname>Lisanti</surname><given-names>CL</given-names></name><name><surname>Tanowitz</surname><given-names>HB</given-names></name><name><surname>Howell</surname><given-names>A</given-names></name><name><surname>Martinez-Outschoorn</surname><given-names>UE</given-names></name><etal/></person-group>. <article-title>Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease</article-title>. <source>Oncotarget.</source> (<year>2015</year>) <volume>6</volume>:<fpage>4569</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.3174</pub-id><pub-id pub-id-type="pmid">25625193</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Francesco</surname><given-names>EM</given-names></name><name><surname>Bonuccelli</surname><given-names>G</given-names></name><name><surname>Maggiolini</surname><given-names>M</given-names></name><name><surname>Sotgia</surname><given-names>F</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name></person-group>. <article-title>Vitamin C and doxycycline: a synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs)</article-title>. <source>Oncotarget.</source> (<year>2017</year>) <volume>8</volume>:<fpage>67269</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.18428</pub-id><pub-id pub-id-type="pmid">28978032</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisner</surname><given-names>V</given-names></name><name><surname>Picard</surname><given-names>M</given-names></name><name><surname>Hajn&#x000f3;czky</surname><given-names>G</given-names></name></person-group>. <article-title>Mitochondrial dynamics in adaptive and maladaptive cellular stress responses</article-title>. <source>Nat Cell Biol.</source> (<year>2018</year>) <volume>20</volume>:<fpage>755</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1038/s41556-018-0133-0</pub-id><pub-id pub-id-type="pmid">29950571</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maycotte</surname><given-names>P</given-names></name><name><surname>Mar&#x000ed;n-Hern&#x000e1;ndez</surname><given-names>A</given-names></name><name><surname>Goyri-Aguirre</surname><given-names>M</given-names></name><name><surname>Anaya-Ruiz</surname><given-names>M</given-names></name><name><surname>Reyes-Leyva</surname><given-names>J</given-names></name><name><surname>Cort&#x000e9;s-Hern&#x000e1;ndez</surname><given-names>P</given-names></name></person-group>. <article-title>Mitochondrial dynamics and cancer</article-title>. <source>Tumour Biol.</source> (<year>2017</year>) <volume>39</volume>:<fpage>1010428317698391</fpage>. <pub-id pub-id-type="doi">10.1177/1010428317698391</pub-id><pub-id pub-id-type="pmid">28468591</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trotta</surname><given-names>AP</given-names></name><name><surname>Chipuk</surname><given-names>JE</given-names></name></person-group>. <article-title>Mitochondrial dynamics as regulators of cancer biology</article-title>. <source>Cell Mol Life Sci.</source> (<year>2017</year>) <volume>74</volume>:<fpage>1999</fpage>&#x02013;<lpage>2017</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-016-2451-3</pub-id><pub-id pub-id-type="pmid">28083595</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youle</surname><given-names>RJ</given-names></name><name><surname>van der Bliek</surname><given-names>AM</given-names></name></person-group>. <article-title>Mitochondrial fission, fusion, and stress</article-title>. <source>Science.</source> (<year>2012</year>) <volume>337</volume>:<fpage>1062</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1126/science.1219855</pub-id><pub-id pub-id-type="pmid">22936770</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group>. <article-title>Mitochondrial dynamics and metastasis</article-title>. <source>Cell Mol Life Sci.</source> (<year>2019</year>) <volume>76</volume>:<fpage>827</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-018-2961-2</pub-id><pub-id pub-id-type="pmid">30415375</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westermann</surname><given-names>B</given-names></name></person-group>. <article-title>Bioenergetic role of mitochondrial fusion and fission</article-title>. <source>Biochim Biophys Acta.</source> (<year>2012</year>) <volume>1817</volume>:<fpage>1833</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbabio.2012.02.033</pub-id><pub-id pub-id-type="pmid">22409868</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandre-Babbe</surname><given-names>S</given-names></name><name><surname>van der Bliek</surname><given-names>AM</given-names></name></person-group>. <article-title>The novel tail-anchored membrane protein MFF controls mitochondrial and peroxisomal fission in mammalian cells</article-title>. <source>Mol Biol Cell.</source> (<year>2008</year>) <volume>19</volume>:<fpage>2402</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.e07-12-1287</pub-id><pub-id pub-id-type="pmid">18353969</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otera</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Cleland</surname><given-names>MM</given-names></name><name><surname>Setoguchi</surname><given-names>K</given-names></name><name><surname>Yokota</surname><given-names>S</given-names></name><name><surname>Youle</surname><given-names>RJ</given-names></name><etal/></person-group>. <article-title>MFF is an essential factor for mitochondrial recruitment of Drp1 during mitochondrial fission in mammalian cells</article-title>. <source>J Cell Biol.</source> (<year>2010</year>) <volume>191</volume>:<fpage>1141</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.201007152</pub-id><pub-id pub-id-type="pmid">21149567</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>CS</given-names></name><name><surname>Osellame</surname><given-names>LD</given-names></name><name><surname>Laine</surname><given-names>D</given-names></name><name><surname>Koutsopoulos</surname><given-names>OS</given-names></name><name><surname>Frazier</surname><given-names>AE</given-names></name><name><surname>Ryan</surname><given-names>MT</given-names></name></person-group>. <article-title>MiD49 and MiD51, new components of the mitochondrial fission machinery</article-title>. <source>EMBO Rep.</source> (<year>2011</year>) <volume>12</volume>:<fpage>565</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1038/embor.2011.54</pub-id><pub-id pub-id-type="pmid">21508961</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Westrate</surname><given-names>LM</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Page</surname><given-names>C</given-names></name><name><surname>Voeltz</surname><given-names>GK</given-names></name></person-group>. <article-title>Multiple dynamin family members collaborate to drive mitochondrial division</article-title>. <source>Nature.</source> (<year>2016</year>) <volume>540</volume>:<fpage>139</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1038/nature20555</pub-id><pub-id pub-id-type="pmid">27798601</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Chan</surname><given-names>DC</given-names></name></person-group>. <article-title>The mitochondrial fission receptor Mff selectively recruits oligomerized Drp1</article-title>. <source>Mol Biol Cell.</source> (<year>2015</year>) <volume>26</volume>:<fpage>4466</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.E15-08-0591</pub-id><pub-id pub-id-type="pmid">26446846</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westermann</surname><given-names>B</given-names></name></person-group>. <article-title>Mitochondrial fusion and fission in cell life and death</article-title>. <source>Nat Rev Mol Cell Biol.</source> (<year>2010</year>) <volume>11</volume>:<fpage>872</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3013</pub-id><pub-id pub-id-type="pmid">21102612</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>FL</given-names></name><name><surname>Harrison</surname><given-names>H</given-names></name><name><surname>Spence</surname><given-names>K</given-names></name><name><surname>Ablett</surname><given-names>MP</given-names></name><name><surname>Sim&#x000f5;es</surname><given-names>BM</given-names></name><name><surname>Farnie</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>A detailed mammosphere assay protocol for the quantification of breast stem cell activity</article-title>. <source>J Mammary Gland Biol Neoplasia.</source> (<year>2012</year>) <volume>17</volume>:<fpage>111</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s10911-012-9255-3</pub-id><pub-id pub-id-type="pmid">22665270</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>R</given-names></name><name><surname>Harrison</surname><given-names>H</given-names></name><name><surname>Hulit</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name><name><surname>Sotgia</surname><given-names>F</given-names></name></person-group>. <article-title>Mitochondria as new therapeutic targets for eradicating cancer stem cells: quantitative proteomics and functional validation via MCT1/2 inhibition</article-title>. <source>Oncotarget.</source> (<year>2014</year>) <volume>5</volume>:<fpage>11029</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.2789</pub-id><pub-id pub-id-type="pmid">25415228</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Francesco</surname><given-names>EM</given-names></name><name><surname>Maggiolini</surname><given-names>M</given-names></name><name><surname>Tanowitz</surname><given-names>HB</given-names></name><name><surname>Sotgia</surname><given-names>F</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name></person-group>. <article-title>Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for optimizing anti-angiogenic therapy</article-title>. <source>Oncotarget.</source> (<year>2017</year>) <volume>8</volume>:<fpage>56126</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.18445</pub-id><pub-id pub-id-type="pmid">28915578</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotgia</surname><given-names>F</given-names></name><name><surname>Ozsvari</surname><given-names>B</given-names></name><name><surname>Fiorillo</surname><given-names>M</given-names></name><name><surname>De Francesco</surname><given-names>EM</given-names></name><name><surname>Bonuccelli</surname><given-names>G</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name></person-group>. <article-title>A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX</article-title>. <source>Cell Cycle.</source> (<year>2018</year>) <volume>17</volume>:<fpage>2091</fpage>&#x02013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1080/15384101.2018.1515551</pub-id><pub-id pub-id-type="pmid">30257595</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Francesco</surname><given-names>EM</given-names></name><name><surname>&#x000d3;zsv&#x000e1;ri</surname><given-names>B</given-names></name><name><surname>Sotgia</surname><given-names>F</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name></person-group>. <article-title>Dodecyl-TPP targets mitochondria and potently eradicates Cancer Stem Cells (CSCs): synergy with FDA-approved drugs and natural compounds (vitamin C and berberine)</article-title>. <source>Front Oncol.</source> (<year>2019</year>) <volume>9</volume>:<fpage>615</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2019.00615</pub-id><pub-id pub-id-type="pmid">31440463</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guha</surname><given-names>M</given-names></name><name><surname>Avadhani</surname><given-names>NG</given-names></name></person-group>. <article-title>Mitochondrial retrograde signaling at the crossroads of tumor bioenergetics, genetics and epigenetics</article-title>. <source>Mitochondrion.</source> (<year>2013</year>) <volume>13</volume>:<fpage>577</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.mito.2013.08.007</pub-id><pub-id pub-id-type="pmid">24004957</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Pettazzoni</surname><given-names>P</given-names></name><name><surname>Lyssiotis</surname><given-names>CA</given-names></name><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>N</given-names></name><name><surname>Marchesini</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function</article-title>. <source>Nature.</source> (<year>2014</year>) <volume>514</volume>:<fpage>628</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1038/nature13611</pub-id><pub-id pub-id-type="pmid">25119024</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuy&#x000e0;s</surname><given-names>E</given-names></name><name><surname>Verdura</surname><given-names>S</given-names></name><name><surname>Folguera-Blasco</surname><given-names>N</given-names></name><name><surname>Bastidas-Velez</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>&#x000c1;G</given-names></name><name><surname>Alarc&#x000f3;n</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Mitostemness</article-title>. <source>Cell Cycle.</source> (<year>2018</year>) <volume>17</volume>:<fpage>918</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1080/15384101.2018.1467679</pub-id><pub-id pub-id-type="pmid">29886796</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katajisto</surname><given-names>P</given-names></name><name><surname>Dohla</surname><given-names>J</given-names></name><name><surname>Chaffer</surname><given-names>CL</given-names></name><name><surname>Pentinmikko</surname><given-names>N</given-names></name><name><surname>Marjanovic</surname><given-names>N</given-names></name><name><surname>Iqbal</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Asymmetric apportioning of aged mitochondria between daughter cells is required for stemness</article-title>. <source>Science.</source> (<year>2015</year>) <volume>348</volume>:<fpage>340</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1126/science.1260384</pub-id><pub-id pub-id-type="pmid">25837514</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiorillo</surname><given-names>M</given-names></name><name><surname>Peiris-Pag&#x000e8;s</surname><given-names>M</given-names></name><name><surname>Sanchez-Alvarez</surname><given-names>R</given-names></name><name><surname>Bartella</surname><given-names>L</given-names></name><name><surname>Di Donna</surname><given-names>L</given-names></name><name><surname>Dolce</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism</article-title>. <source>Biochim Biophys Acta Bioenerg.</source> (<year>2018</year>) <volume>1859</volume>:<fpage>984</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbabio.2018.03.018</pub-id><pub-id pub-id-type="pmid">29626418</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonuccelli</surname><given-names>G</given-names></name><name><surname>Sotgia</surname><given-names>F</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name></person-group>. <article-title>Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways</article-title>. <source>Aging.</source> (<year>2018</year>) <volume>10</volume>:<fpage>1867</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.18632/aging.101483</pub-id><pub-id pub-id-type="pmid">30153655</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozsvari</surname><given-names>B</given-names></name><name><surname>Fiorillo</surname><given-names>M</given-names></name><name><surname>Bonuccelli</surname><given-names>G</given-names></name><name><surname>Cappello</surname><given-names>AR</given-names></name><name><surname>Frattaruolo</surname><given-names>L</given-names></name><name><surname>Sotgia</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Mitoriboscins: mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast</article-title>. <source>Oncotarget.</source> (<year>2017</year>) <volume>8</volume>:<fpage>67457</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.19084</pub-id><pub-id pub-id-type="pmid">28978045</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozsvari</surname><given-names>B</given-names></name><name><surname>Sotgia</surname><given-names>F</given-names></name><name><surname>Simmons</surname><given-names>K</given-names></name><name><surname>Trowbridge</surname><given-names>R</given-names></name><name><surname>Foster</surname><given-names>R</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name></person-group>. <article-title>Mitoketoscins: novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)</article-title>. <source>Oncotarget.</source> (<year>2017</year>) <volume>8</volume>:<fpage>78340</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.21259</pub-id><pub-id pub-id-type="pmid">29108233</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiorillo</surname><given-names>M</given-names></name><name><surname>Lamb</surname><given-names>R</given-names></name><name><surname>Tanowitz</surname><given-names>HB</given-names></name><name><surname>Cappello</surname><given-names>AR</given-names></name><name><surname>Martinez-Outschoorn</surname><given-names>UE</given-names></name><name><surname>Sotgia</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)</article-title>. <source>Aging.</source> (<year>2016</year>) <volume>8</volume>:<fpage>1593</fpage>&#x02013;<lpage>607</lpage>. <pub-id pub-id-type="doi">10.18632/aging.100983</pub-id><pub-id pub-id-type="pmid">27344270</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picard</surname><given-names>M</given-names></name><name><surname>Shirihai</surname><given-names>OS</given-names></name><name><surname>Gentil</surname><given-names>BJ</given-names></name><name><surname>Burelle</surname><given-names>Y</given-names></name></person-group>. <article-title>Mitochondrial morphology transitions and functions: implications for retrograde signaling?</article-title>
<source>Am J Physiol Regul Integr Comp Physiol.</source> (<year>2013</year>) <volume>304</volume>:<fpage>R393</fpage>&#x02013;<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1152/ajpregu.00584.2012</pub-id><pub-id pub-id-type="pmid">23364527</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Robotham</surname><given-names>JL</given-names></name><name><surname>Yoon</surname><given-names>Y</given-names></name></person-group>. <article-title>Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2006</year>) <volume>103</volume>:<fpage>2653</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0511154103</pub-id><pub-id pub-id-type="pmid">16477035</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group>. <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell.</source> (<year>2011</year>) <volume>144</volume>:<fpage>646</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlova</surname><given-names>NN</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group>. <article-title>The emerging hallmarks of cancer metabolism</article-title>. <source>Cell Metab.</source> (<year>2016</year>) <volume>23</volume>:<fpage>27</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2015.12.006</pub-id><pub-id pub-id-type="pmid">26771115</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name></person-group>. <article-title>LATS2 promotes apoptosis in non-small cell lung cancer A549 cells via triggering Mff-dependent mitochondrial fission and activating the JNK signaling pathway</article-title>. <source>Biomed Pharmacother.</source> (<year>2019</year>) <volume>109</volume>:<fpage>679</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.10.097</pub-id><pub-id pub-id-type="pmid">30551520</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>JH</given-names></name><name><surname>Chae</surname><given-names>YC</given-names></name><name><surname>Kossenkov</surname><given-names>AV</given-names></name><name><surname>Lee</surname><given-names>YG</given-names></name><name><surname>Tang</surname><given-names>H-Y</given-names></name><name><surname>Agarwal</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>MFF regulation of mitochondrial cell death is a therapeutic target in cancer</article-title>. <source>Cancer Res</source>. (<year>2019</year>) <volume>79</volume>:<fpage>6215</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-1982</pub-id><pub-id pub-id-type="pmid">31582380</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Dynamin-related protein 1-mediated mitochondrial fission contributes to IR&#x02212;783-induced apoptosis in human breast cancer cells</article-title>. <source>J Cell Mol Med.</source> (<year>2018</year>) <volume>22</volume>:<fpage>4474</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.13749</pub-id><pub-id pub-id-type="pmid">29993201</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Hong</surname><given-names>X</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Excessive mitochondrial fragmentation triggered by erlotinib promotes pancreatic cancer PANC-1 cell apoptosis via activating the mROS-HtrA2/Omi pathways</article-title>. <source>Cancer Cell Int.</source> (<year>2018</year>) <volume>18</volume>:<fpage>165</fpage>. <pub-id pub-id-type="doi">10.1186/s12935-018-0665-1</pub-id><pub-id pub-id-type="pmid">30377412</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris-Pag&#x000e8;s</surname><given-names>M</given-names></name><name><surname>Bonuccelli</surname><given-names>G</given-names></name><name><surname>Sotgia</surname><given-names>F</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name></person-group>. <article-title>Mitochondrial fission as a driver of stemness in tumor cells: mDIVI1 inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling</article-title>. <source>Oncotarget.</source> (<year>2018</year>) <volume>9</volume>:<fpage>13254</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.24285</pub-id><pub-id pub-id-type="pmid">29568355</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bordt</surname><given-names>EA</given-names></name><name><surname>Clerc</surname><given-names>P</given-names></name><name><surname>Roelofs</surname><given-names>BA</given-names></name><name><surname>Saladino</surname><given-names>AJ</given-names></name><name><surname>Tretter</surname><given-names>L</given-names></name><name><surname>Adam-Vizi</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>The putative Drp1 inhibitor mdivi-1 is a reversible mitochondrial complex I inhibitor that modulates reactive oxygen species</article-title>. <source>Dev Cell.</source> (<year>2017</year>) <volume>40</volume>:<fpage>583</fpage>&#x02013;<lpage>94</lpage>.e6. <pub-id pub-id-type="doi">10.1016/j.devcel.2017.02.020</pub-id><pub-id pub-id-type="pmid">28350990</pub-id></mixed-citation></ref></ref-list></back></article>